FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

•

STATEMENT	OF (	CHANGES	IN BEN	<b>EFICIAL</b>	<b>OWNERSHIP</b>

OMB APPROVAL								
OMB Number: 3235-028								
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  HEALY JAMES				2. Issuer Name and Ticker or Trading Symbol Coherus BioSciences, Inc. [ CHRS ]					(Ch	5. Relationship of Reporting Person(s) to Issuer Check all applicable)  X Director 10% Owner						
	INNOVA	NVESTMENTS	*		3. Date of Earliest Transaction (Month/Day/Year) 01/10/2020						Officer below)	(give title		Other (specifically below)	pecify	
3000 SAND HILL ROAD, BLDG. 4, SUITE 250			0 4	4. If Amendment, Date of Original Filed (Month/Day/Year)						6. Individual or Joint/Group Filing (Check Applicable Line)						
(Street) MENLO	PARK C	A	94025									X Form fi	led by More		ting Person One Report	
(City)	(S	tate)	(Zip)													
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																
Date			2. Transacti Date Month/Day	Execution Date,		Code (Ins	ransaction Disposed Of (D) (Instr. 3, 4			Beneficia	es Formally (D) (I) (I		m: Direct or Indirect Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
								Code V	Amount	(A) or (D)	Price	Transact (Instr. 3 a	ion(s)			nstr. 4)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																
1. Title of Derivative Conversion or Exercise Price of Derivative Security  (Instr. 3)  2. Conversion Date (Month/Day/Year)  3A. Deemed Execution Date, if any (Month/Day/Year)		Code	ransaction of ode (Instr. Derivative		Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)			
				Code	e V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares					
Stock Option (Right to Buy)	\$17.73	01/10/2020		A		20,000		(1)	01/10/2030	Common Stock	20,000	\$0.00	20,000		D	

## **Explanation of Responses:**

1. The underlying shares subject to the option vest and become exercisable as to 1/12th of the total number of shares subject to the option in successive, equal monthly installments measured from January 1, 2020, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.

/s/ Jean-Frederic Viret, as Attorney-in-Fact for James I.

Attorney-in-Fact for James I. 01/14/2020

Healy, M.D., Ph.D.

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.